A crowded proton pump inhibitor market awaits Pfizer Inc.after acquiring rights to an OTC Nexium, but a switch of the esomeprazole magnesium product could encounter safety questions even with similar molecules already available nonprescription for frequent heartburn.
Pfizer will make an upfront payment of $250 million to AstraZeneca PLC for global rights to market a potential...